Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24854789 | 0.82 | GAA (0.40) | GAAL3MBTL1CYP1A2 | |
| SCHEMBL7803296 | 0.79 | GAA (0.31) | GAA | |
| SCHEMBL29077721 | 0.76 | ALDH1A1 (0.38) | ALDH1A1TSHRTDP1CYP1A2 | |
| SCHEMBL9750789 | 0.74 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1CYP1A2 | |
| SCHEMBL19965920 | 0.74 | ALDH1A1 (0.36) | ALDH1A1TSHRTDP1CYP1A2 | |
| SCHEMBL21579250 | 0.73 | CHRM3 (0.36) | ALDH1A1TSHRTDP1 | |
| SCHEMBL25036313 | 0.72 | PIN1 (0.31) | GAAL3MBTL1 | |
| SCHEMBL16919248 | 0.71 | ALDH1A1 (0.33) | ALDH1A1TSHRTDP1 | |
| SCHEMBL13760354 | 0.71 | ALDH1A1 (0.33) | ALDH1A1TSHRTDP1 | |
| SCHEMBL19184823 | 0.71 | SHBG (0.35) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-20 | — | — | US | disclosed |
| US-10774064-B2 | Potassium channel modulators | CADENT THERAPEUTICS, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-09 | — | — | US | disclosed |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981926-B2 | Substituted thiohydantoin derivatives as androgen receptor antagonists | AR, SHBG, NR5A1 | GAA 4196/4885L3MBTL1 2252/4885ALDH1A1 350/4885 |
| US-10774064-B2 | Potassium channel modulators | KCNJ11, KCNJ2, KCNJ1 | GAA 1172/4885L3MBTL1 4021/4885ALDH1A1 1320/4885 |
| US-20190218200-A1 | POTASSIUM CHANNEL MODULATORS | KCNJ11, KCNJ2, KCNJ1 | GAA 1172/4885L3MBTL1 4021/4885ALDH1A1 1320/4885 |
| US-20200109150-A1 | Substituted Thiohydantoin Derivatives As Androgen Receptor Antagonists | AR, SHBG, NR5A1 | GAA 4196/4885L3MBTL1 2252/4885ALDH1A1 350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.